Anthony J. Olszanski
Expertise in
15
conditions

Dr. Anthony J. Olszanski

Oncology
Fox Chase Cancer Center
333 Cottman Avenue, 
Philadelphia, PA 
Expertise in
15
conditions
Fox Chase Cancer Center
333 Cottman Avenue, 
Philadelphia, PA 

Overview

Anthony Olszanski is an Oncologist practicing medicine in Philadelphia, Pennsylvania.

Dr. Olszanski is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Melanoma, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), and Squamous Cell Lung Carcinoma.

Dr. Olszanski is board certified in American Board Of Internal Medicine - Medical Oncology. He is actively involved in clinical research, co-authoring 94 peer reviewed articles and participating in 18 clinical trials.

Graduate Institution

BS, Pharmacy, University Of Montana, Missoula, MT, 1990

Residency

Internal Medicine, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, 1996-1999

Specialties

Oncology

Licenses

Internal Medicine in PA

Board Certifications

American Board Of Internal Medicine - Medical Oncology

Fellowships

Clinical Pharmacology/Toxicology, Oncology Phase I Program, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH 2002-2004
Hematology/Oncology, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, 1999-2002

Hospital Affiliations

Temple University Hospital
Temple Health - Chestnut Hill Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Fox Chase Cancer Center
333 Cottman Avenue, Philadelphia, PA 19111

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

Phase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4ᶜ¹º³²T in HLA-A2+ Subjects With MAGE-A4 Positive Tumors
Phase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4ᶜ¹º³²T in HLA-A2+ Subjects With MAGE-A4 Positive Tumors
Enrollment Status: Active_not_recruiting
Publish Date: June 04, 2026
Intervention Type: Genetic, Radiation
Study Drug: Autologous Genetically Modified MAGE-A4c1032 T-Cells
Study Phase: Phase 1
An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
Enrollment Status: Completed
Publish Date: April 08, 2026
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 As Monotherapy Or In Combination With Either Nivolumab Or Pembrolizumab In HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 As Monotherapy Or In Combination With Either Nivolumab Or Pembrolizumab In HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
Enrollment Status: Active_not_recruiting
Publish Date: April 07, 2026
Intervention Type: Genetic
Study Phase: Phase 1
Phase 1 Cell Dose Escalation Study to Assess the Safety and Tolerability of Genetically Engineered MAGE-A10ᶜ⁷⁹⁶T in HLA-A2+ Subjects With MAGE-A10 Positive Urothelial, Melanoma or Head and Neck Tumors
Phase 1 Cell Dose Escalation Study to Assess the Safety and Tolerability of Genetically Engineered MAGE-A10ᶜ⁷⁹⁶T in HLA-A2+ Subjects With MAGE-A10 Positive Urothelial, Melanoma or Head and Neck Tumors
Enrollment Status: Completed
Publish Date: February 04, 2026
Intervention Type: Genetic
Study Phase: Phase 1
An Open-label, Dose Escalation and Expansion, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of TAK-500, a Novel Stimulator of Interferon Genes Agonist, as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advanced or Metastatic Solid Tumors
An Open-label, Dose Escalation and Expansion, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of TAK-500, a Novel Stimulator of Interferon Genes Agonist, as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: January 22, 2026
Intervention Type: Drug
Study Drugs: TAK-500, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase 1, Open-label, Multiple-ascending Dose Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metastatic or Locally Advanced Solid Tumors
A Phase 1, Open-label, Multiple-ascending Dose Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metastatic or Locally Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: September 16, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Enrollment Status: Completed
Publish Date: August 14, 2025
Intervention Type: Drug
Study Drugs: INCAGN01876, Nivolumab, Ipilimumab
Study Phase: Phase 1/Phase 2
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid and Hematological Malignancies
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid and Hematological Malignancies
Enrollment Status: Completed
Publish Date: March 04, 2025
A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects With Advanced Refractory Cancers
A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects With Advanced Refractory Cancers
Enrollment Status: Completed
Publish Date: February 27, 2025
Intervention Type: Biological, Drug
Study Drugs: INT230-6, Pembrolizumab, Ipilimumab
Study Phase: Phase 1/Phase 2
A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination With Anticancer Agents in Subjects With Selected Advanced Solid Tumors
A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination With Anticancer Agents in Subjects With Selected Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

94 Total Publications

Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.
Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: June 15, 2026
Similar Doctors
Expertise in
17
conditions
Expertise in
17
conditions
Referral may be required

Fox Chase Cancer Center

333 Cottman Avenue, 
Philadelphia, PA 
 (5.2 miles away)
888-369-2427
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Hossein Borghaei is an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Borghaei is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer. Dr. Borghaei is board certified in American Board Of Internal Medicine - Medical Oncology.

Expertise in
18
conditions
Expertise in
18
conditions
Referral may be required

Fox Chase Cancer Center

333 Cottman Avenue, 
Philadelphia, PA 
 (5.2 miles away)
888-369-2427
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Daniel Geynisman is an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Geynisman is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Muscle Invasive Bladder Cancer, Bladder Cancer, Nephrectomy, and Orchiectomy. Dr. Geynisman is board certified in American Board Of Internal Medicine - Medical Oncology.

Expertise in
15
conditions
Expertise in
15
conditions
Referral may be required

Fox Chase Cancer Center

333 Cottman Avenue, 
Philadelphia, PA 
 (5.2 miles away)
888-369-2427
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Elizabeth Plimack is an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Plimack is highly rated in 15 conditions, according to our data. Her clinical expertise encompasses Renal Cell Carcinoma (RCC), Muscle Invasive Bladder Cancer, Bladder Cancer, Nephrectomy, and Orchiectomy. Dr. Plimack is board certified in American Board Of Internal Medicine - Medical Oncology.

Frequently Asked Questions about Dr. Anthony J. Olszanski

How do I make an appointment with Dr. Anthony J. Olszanski?

You can book an appointment with Dr. Anthony J. Olszanski by calling their office at 888-369-2427. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Anthony J. Olszanski a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Anthony J. Olszanski is classified as an Elite expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Anthony J. Olszanski specialize in?

While Dr. Anthony J. Olszanski is a Oncology, they have specific expertise in Melanoma, Pleuropulmonary Blastoma, and Small Cell Lung Cancer (SCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Anthony J. Olszanski participate in research or clinical trials?

Yes. Dr. Anthony J. Olszanski has published 94 articles and abstracts on conditions like Melanoma. You can view a list of Dr. Anthony J. Olszanski's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Anthony J. Olszanski accept my insurance?

Dr. Anthony J. Olszanski accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 888-369-2427 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Olszanski's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 37 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile